Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

Diabetes Research and Clinical Practice

Volumn 108, Issue 2, 2015, Pages 350-359

  Home, Philip D ^a   Dain, Marie Paule ^b   Freemantle, Nick ^c   Kawamori, Ryuzo ^d   Pfohl, Martin ^e   Brette, Sandrine ^f   Pilorget, Valérie ^b   Scherbaum, Werner A ^g   Vespasiani, Giacomo ^h   Vincent, Maya ^b   Balkau, Beverley ⁱ  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SANOFI   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d JUNTENDO UNIVERSITY   (Japan)

^e Evangelisches BETHESDA Krankenhaus zu Duisburg GmbH   (Germany)

^f Department of Biostatistics   (France)

^g UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^h Madonna del Soccorso Hospital   (Italy)

ⁱ INSERM   (France)

Author keywords

CREDIT; Glucose lowering mediations; Glycaemic control; Hypoglycaemia; Insulin regimens; Non interventional study

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT CHANGE; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATIENT CARE PLANNING; RETROSPECTIVE STUDY; TIME; TRENDS;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT CARE PLANNING; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84927912381     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.01.030     Document Type: Article

References (31)

1. International Diabetes Federation: global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014, 104(1):1-52.
2. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
3. NICE. Blood-glucose-lowering therapy for type 2 diabetes. National Institute for Health and Care Excellence. [accessed 12.06.13]. http://pathways.nice.org.uk/pathways/diabetes#path=view%3A/pathways/diabetes/blood-glucose-lowering-therapy-for-type-2-diabetes.xml%26content=view-node%3Anodes-starting-insulin-particularly-if-hyperglycaemia-is-marked.
4. Home P., Naggar N.E., Khamseh M., Gonzalez-Galvez G., Shen C., Chakkarwar P., et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract 2011, 94(3):352-363.
5. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357(17):1716-1730.
6. Strojek K., Bebakar W.M., Khutsoane D.T., Pesic M., Smahelova A., Thomsen H.F., et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009, 25(12):2887-2894.
7. Eliasson B., Ekstrom N., Bruce W.S., Oden A., Fard M.P., Svensson A.M. Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naive type 2 diabetes patients: registry-based observational study in clinical practice. Diabetes Ther 2014, 5(1):243-254.
8. Gordon J., Pockett R.D., Tetlow A.P., McEwan P., Home P.D. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 2010, 64(12):1609-1618.
9. Hall G.C., McMahon A.D., Dain M.P., Wang E., Home P.D. Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med 2013, 30(6):681-686.
10. Khunti K., Damci T., Meneghini L., Pan C.Y., Yale J.F. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 2012, 14(7):654-661.
11. Meneghini L.F., Dornhorst A., Sreenan S. Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin 2009, 25(4):1029-1035.
12. Freemantle N., Balkau B., Danchin N., Wang E., Marre M., Vespasiani G., et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 2012, 14(10):901-909.
13. Jeppsson J.O., Kobold U., Barr J., Finke A., Hoelzel W., Hoshino T., et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002, 40(1):78-89.
14. Little R.R., Rohlfing C.L., Wiedmeyer H.M., Myers G.L., Sacks D.B., Goldstein D.E. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001, 47(11):1985-1992.
15. Hall G.C., McMahon A.D., Carroll D., Home P.D. Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study. Pharmacoepidemiol Drug Saf 2012, 21(3):305-313.
16. Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367(4):319-328.
17. Hall G.C., McMahon A.D., Dain M.P., Home P.D. A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract 2011, 94(3):442-448.
18. Karter A.J., Moffet H.H., Liu J., Parker M.M., Ahmed A.T., Go A.S., et al. Glycemic response to newly initiated diabetes therapies. Am J Manag Care 2007, 13(11):598-606.
19. Fonseca V., Davidson J., Home P., Snyder J., Jellinger P., Dyhr T.A., et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010, 26(7):1621-1628.
20. Deacon C.F., Mannucci E., Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes - a review and meta analysis. Diabetes Obes Metab 2012, 14(8):762-767.
21. DeFronzo R.A., Stonehouse A.H., Han J., Wintle M.E. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010, 27(3):309-317.
22. Riddle M.C., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26(11):3080-3086.
23. Pfohl M., Dippel F.W., Kostev K., Fuchs S., Kotowa W. Different persistence on initial basal supported oral therapy in Type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany. Int J Clin Pharmacol Ther 2010, 48(11):761-766.
24. Quinzler R., Ude M., Franzmann A., Feldt S., Schussel K., Leuner K., et al. Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin. Int J Clin Pharmacol Ther 2012, 50(1):24-32.
25. Raz I. Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013, 36(Suppl. 2):S139-S144.
26. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310(6972):83-88.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
28. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
29. Balkau B., Home P.D., Vincent M., Marre M., Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014, 37(8):2108-2113.
30. UK Hypoglycaemia Stzzudy Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50(6):1140-1147.
31. Valensi P., Benroubi M., Borzi V., Gumprecht J., Kawamori R., Shaban J., et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 2009, 63(3):522-531.